N&PD Moderators: Skorpio
You should upgrade or use an alternative browser.Ketamine salts solubility
PEPTIS
I want my FLUCTINYL to be 10/1 with this
Nice enzymatic activity
ARG!
1-phenylguanidine
MARSHA EMERY
1-(3,4-methylenedioxyphenyl)-3-ethylguanidine
Some additional surprises, different packages
makes you breath
FLACTAMAX
JERRY COKE
LITTERALLY CALL THIS ONE: UTOPIUM
Melanocortin
Orexin
Oxytocin
Gamma secretase
Gaba gamma etc
Monoamine oxidase
Adenosine
Vanilloid receptor
Tadadimtatadam
0.5mg for 7mg PUP FLEX for 0.1mg BREATHY for 2.4mg of my sister's little secret. This one is actually patented by my sister, so we pep it up!izo
Bluelighter
1-phenylguanidine
1-phenylbiguanides are 5ht-3 subtype selective agonists.
snipped:
that the affinities of 3-chlorophenyl- (130) and 2-naphthylgua-
nides (131) which also act as 5-HT3 receptor agonists manifest the
highest (by one or two orders of magnitude) affinities among other
structurally related arylguanides 233 and can thus be regarded as
representatives of a new structural class of serotonin receptor
agonists.
i think most of small molecule ligands have been done by now.Rectify
Bluelighter
Rectify
Bluelighter
HORSEPOWERizo
Bluelighter
this stuff will fuck you up.izo
Bluelighter
Latest advances in cannabinoid receptor agonists
Abstract
Background: Since the discovery of cannabinoid receptors and their endogenous ligands in early 1990s, the endocannabinoid system has been shown to play a vital role in several pathophysiological processes. It has been targeted for the treatment of several diseases including neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, Huntington's disease and MS), cancer, obesity, inflammatory bowel disease, neuropathic and inflammatory pain. The last decade has witnessed remarkable advances in the development of cannabinergic ligands displaying high selectivity and potency towards two subtypes of cannabinoid receptors, namely CB1 and CB2.
Objective: In this review, we highlight the latest advances made in the development of cannabinoid agonists and summarize recently disclosed, novel chemical scaffolds as CB-selective agonists in patents that appeared during January 2008 - June 2009.
Methods: Data presented here are obtained through the search of PubMed for research articles and reviews, and the website of European patents (http://ep.espacenet.com), SciFinder Scholar and US patents (www.uspto.gov).
Conclusions: Our analysis reveals prolific patenting activity mainly in the CB2 selective agonist area. Limiting the BBB penetrability, thereby, leading to peripherally restricted CB1/CB2 agonists and enhancing CB2-selectivity emerge as likely prerequisites for avoidance of adverse central CB1 mediated side effects.
Latest advances in cannabinoid receptor agonists - PubMed
pubmed.ncbi.nlm.nih.gov
2009 - Latest advances in cannabinoid receptor agonists.pdf
drive.google.com
best paper on the recent ongoing in cannabinoid ligands, lots of interesting structures.Rectify
Bluelighter
PHISH
1-(3,4-dichloro-2-methoxyphenyl)-2-amino-1-chloropropane
A LIVE ONE
SADDUCE
1-(3,4-methylenedioxyphenyl)-2-methylamino-1-(methylthio)propane
PHARISEE
1-(4-trifluoromethylphenyl)-2-aminopropane
(
4-HOT
1-(4-hydroxyindole-3-yl)-2-aminoethane
4-HydrOxyTryptamine
THE_GOOD_SAMARITAN
1-(2-(methylthio)-3,4-dibromophenyl)-2-methylamino-propane
PENICILLIN_M
(2S,5R,6R)-2-carbomethoxy-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane
aka penicillin G methyl ester
so obvious it hurts
penetrates CSF much better than its parent compound, pen G (benzyl penicillin)